Health Care • Biotechnology: Pharmaceutical Preparations
$44.39 ▼ -0.51
(-1.14%)
MKT CAP: $7.38B • VOL: 1.83M
52W L $42 52W H $87
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$37
MEDIAN
$50
MEAN
$51
HIGH
$60
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE IONS TAPE
IONS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $53.71 | $51.05 | 2025-02-14 | $40.39 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $55.93 | $52.38 | 2025-02-06 | $41.73 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $50.60 | $48.83 | 2025-01-29 | $42.61 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $45.28 | — | 2025-01-17 | $43.50 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $39.06 | $42.17 | 2025-01-09 | $39.51 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $52.82 | $46.17 | 2024-12-18 | $38.62 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $43.06 | $44.83 | 2024-12-04 | $41.28 | -4.3% | 48% | C |